Sentences with phrase «developing immunotherapies»

Starting operations in 2012, iTeos Therapeutics is a clinical - stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design.

Cancer immunologists focus on developing immunotherapies to boost those natural defenses.

Those developing immunotherapies based on monoclonal antibodies (MAbs) will experience fewer such issues thanks to platform manufacturing technologies, but even they are likely to be priced to perfection.

The company is developing immunotherapies for cancer and prophylactic vaccines against infectious diseases, both based on RNA molecules.

«We thought our assays weren't working,» recalls Markovic, a hematologist and oncologist whose research focuses on developing immunotherapies for melanoma and non-Hodgkin's lymphoma.

• Arcus Biosciences, a Hayward, Calif - based biotech developing immunotherapy drugs, filed for a $ 100 million IPO.

Some of the smaller companies developing immunotherapy drugs could be acquired by the pharmaceutical giants, analysts said.

Juno is developing its immunotherapy product candidate, JCAR017, which is in a Phase I trial, studying patients with B - cell Non-Hodgkin Lymphoma [NHL].

As part of a large NIH - funded effort to develop immunotherapies for this allergy (the Inner City Asthma Consortium, or ICAC), the Sette lab has thus identified dominant epitopes to characterize T cell responses in allergic individuals before and after immunotherapy.

The findings provide a new target for ongoing efforts to develop immunotherapies to harness the immune system to fight cancer and other diseases.

Not exact matches

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $ 7.50 per share.

HOUSTON, April 16, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock.

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders.

CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.

JCAR015 is among CAR T - cell candidates covered by Juno's 10 - year, approximately $ 1 billion global collaboration launched in 2015 to develop and commercialize cancer and autoimmune diseases immunotherapies.

Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies.

Current research is underway to test milk oral immunotherapy as a way to develop tolerance to milk protein.

Judith Gasson, senior associate dean for research at the David Geffen School of Medicine at UCLA and director of the Jonsson Cancer Center, said researchers have long hoped to develop an effective and lasting immunotherapy to fight cancer.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

«What's interesting is that neither drug was developed as an immunotherapy.

In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg ~ Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood - brain barrier.

Sharma had developed a new method for studying how tumors with different characteristics respond to different immunotherapies: She would treat patients before their growths were surgically removed, then analyze the tissue in her lab.

Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this strategy.

«This panel of neutralizing antibodies offers the possibility of developing human monoclonal antibody - based immunotherapy, especially for health care workers,» noted the authors.

Researchers are also working to develop a trial where they will reprogram CAR T cells to identify the CD19 and CD22 proteins simultaneously, enabling them to target the cancer cells from more than one angle with the initial round of T - cell immunotherapy.

The researchers are developing a potential new immunotherapy strategy for melanoma based on their insights into Autoimmune Polyendocrinopathy Type 1, a rare, inherited disorder in which T - cells attack healthy cells and tissues.

Kole Roybal is the 2018 grand prize winner of the inaugural Sartorius & Science Prize for Regenerative Medicine & Cell Therapy, for developing a new class of T cell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the disease.

Medical researchers are working hard to develop effective vaccines and other immunotherapy treatments for pancreatic cancer.

While a postdoctoral fellow at the Naval Medical Research Institute in Bethesda, he developed a system for large - scale efficient culture of lymphocytes that has proved to be the foundation for over 35 early phase clinical trials of adoptive immunotherapy.

Dr. Cooper joined MDACC in 2006 as section chief of cell therapy at the Children's Cancer Hospital, where he cared for children undergoing bone marrow transplantation and led scientific efforts to develop new treatment approaches that pair genetic engineering with immunotherapies.

In collaboration with the Parker Institute for Cancer Immunotherapy (PICI), Wargo's team is developing the first immunotherapy - microbiome clinical trial, with a goal of launching it latImmunotherapy (PICI), Wargo's team is developing the first immunotherapy - microbiome clinical trial, with a goal of launching it latimmunotherapy - microbiome clinical trial, with a goal of launching it later this year.

The researchers from Bochum and Erlangen now plan to employ the gained insights to develop innovative dietary add - on therapies to established immunotherapies in multiple sclerosis.

«Cancer is like a person's thumbprint; each person's cancer is uniquely theirs,» says Bill Hearl, CEO of Immunomic Therapeutics, a clinical stage biotechnology company developing a nucleic acid immunotherapy platform with the potential to treat cancer, allergies and animal health issues.

Though similar to healthy cells, cancer cells often display unique antigens on their surface, which can be exploited to develop cancer immunotherapies.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

To date, researchers have focused on developing anti-CMV immunotherapy around the «fighter» cells — called CD8 T effector cells — that attack and kill virally - infected host cells.

Harari, Coukos and their colleagues will now be applying their findings to an ambitious program to develop and streamline personalized immunotherapies for cancer patients currently underway at the Lausanne Branch of the Ludwig Institute for Cancer Research.

But the addition of rapamycin to immunotherapy even for a short while also allowed the rodents to develop tumor - specific memory CD8 + T cells that remember the specific «signature» of the glioma tumor cells and attacked them swiftly when a tumor was introduced into the brain again.

«As we identify which bacteria have a similar effect in humans, it should be possible to develop probiotic supplements that specifically improve efficacy of immunotherapies,» he says.

Other research at U-M is developing new options for treating brain cancer through immunotherapy — harnessing the immune system to attack cancer cells once an injection of a particular gene therapy is delivered into the brain tumor.

Seres is developing SER - 401, a preclinical stage oral microbiome therapy comprising a consortium of live bacteria to improve the efficacy and safety of immunotherapy.

In my professional career, I have focused both on developing precision medicine agents as well as immunotherapies.

To meet this end, CCIR members take advantage of resources offered by MD Anderson, including the CCSG Shared Resources, Immune Monitoring Core Laboratory and GMP Cell Facility, allowing them to follow the «bench - to - beside» approach to develop and improve cancer immunotherapy in the form of cellular therapy, a vaccine or targeting antibody, either alone or in combination with conventional therapies or newly developed therapies.

She has identified novel immune - modulating activities associated with targeted cancer drugs in preclinical models, and developed synergistic immunotherapy combinations.

The company is developing CAR T - cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases.

The Center for Cancer Immunology Research (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurrence.

Most recently Dr C. Glenn Begley was Chief Scientific Officer at Akriveia Therapeutics, a Californian biotech company focused on discovering and developing the next generation of cancer immunotherapies.

Twenty years ago, James Allison, an immunologist at MD Anderson Cancer Center, was the first to develop an antibody in a class of immunotherapy called checkpoint inhibitors.

Biernacki's research focuses on developing targeted immunotherapy for pediatric acute myeloid leukemia, or AML.